Ipca Laboratories Ltd

Go Back

Ipca Laboratories Ltd

  • Net income for the financial year ended March 31, 2014 was Rs 3,256.25 crore (US$ 538 million)
  • Net profit was Rs 477.37 crores (US$ 79 million)
  • Market share of over 34 per cent
  • Ipca was awarded as ‘Among the 100 Best Companies to Work in India 2010’

For more than 60 years, Ipca has been partnering healthcare globally in over 110 countries and in markets as diverse as Africa, Asia, Australia, Europe and the US.

Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments.

They are one of the world's largest manufacturers and suppliers of over a dozen APIs. These are produced right from the basic stage at manufacturing facilities endorsed by the world's most discerning drug regulatory authorities like US-FDA, UK-MHRA, EDQM-Europe, WHO-Geneva and many more.

Ipca is a therapy leader in India for anti-malarials with a market-share of over 34 per cent with a fast expanding presence in the international market as well. They have leading brands in 5 therapeutic areas, with 4 of our branded formulations being ranked among the Top-300 Indian brands by ORG-IMS.

Source: http://www.ipcalabs.com/

Ipca Laboratories Ltd: Fully-integrated Indian pharmaceutical company

2013 Ipca featured on the 8th position in the list of 'India's Most Admired Companies', in a survey carried out by Fortune India
2006 Ipca launches fixed dose ACT combination for treatment of malaria
1996 Ipca commissioned new API R&D centre at Mumbai
1986 Ipca first API Plant for manufacturing of chloroquine phosphate, set up at Ratlam
1976 Ipca started marketing of sugarcoated chloroquine tablets, first time in India

Updated: December, 2014

India's pharmaceutical sector will touch US$ 45 billion by 2020.
x IBEF : India Brand Equity Foundation